Before a drug is ready for clinical trial management in real patients, it must first be thoroughly tested in animals. The first time it is administered to humans, it must be tested on healthy volunteers to determine whether it is safe, to see how it changes in the body (pharmacokinetics), how it affects the body (pharmacodynamics) and to determine the highest tolerable dosage. This is called a Phase I trial.
In Phase Two trials, or proof of concept trials, the drug is given to a higher number of people who actually have been diagnosed with the disease or condition which the new product has been designed to treat. Information about side effects and adverse events is carefully collected.
At this time, the Phase Two protocol is written at the same time that feasibility studies are being conducted. These two tasks must run together because information from the feasibility feeds into the protocol. The study protocol is the central, legal document in the running of the trial. It includes all medications, laboratory tests and procedures that will take place during the study.
The clinical trial protocol is the central document in the study. It must be written in a way that protects the health and welfare of the patients, provide information on why the trial is being conducted, and describe the inclusion and exclusion criteria for recruiting patients. The level of detail included in the trial protocol goes right down to what temperature the investigational medicinal product (IMP) must be stored.
During feasibility, the study team meets with medical doctors who may or may not become involved in the actual trial. Known as Key Opinion Leaders (KOLs), these doctors provide valuable information about the trial. They offer feedback on the existing protocol and propose changes. Information is gathered as to what resources are necessary at each study center to be able to conduct the trial effectively. A seemingly endless series of iterations of protocol revisions and further feasibility is conducted to arrive at the final trial protocol.
Before any drug may be dispensed to the first patient, the protocol must be approved by the Competent Authority of each country that is participating in the study. In the United States, this is the Food and Drug Administration (FDA). The protocol must also be approved by an ethics committee, whose primary role is to safeguard the rights, dignity and well-being of the patients, and also by an institutional review board for each hospital or other institution where patients will be seen.
The ethics committees are particularly interested in the consent form that must be signed before each patient undergoes any procedures and its accompanying patient information sheet (PIS). The PIS must carefully explain each procedure and any anticipated side effects. Each and every risks that are outlined in a separate document for the participating physicians, called the Investigator's Brochure, must be included in the PIS.
Clinical trial management is a lengthy, complicated process. This is necessary to keep bad drugs out of the marketplace and to protect the safety, dignity and well-being of the subjects. It is also necessary to make sure the research answers the right questions.
In Phase Two trials, or proof of concept trials, the drug is given to a higher number of people who actually have been diagnosed with the disease or condition which the new product has been designed to treat. Information about side effects and adverse events is carefully collected.
At this time, the Phase Two protocol is written at the same time that feasibility studies are being conducted. These two tasks must run together because information from the feasibility feeds into the protocol. The study protocol is the central, legal document in the running of the trial. It includes all medications, laboratory tests and procedures that will take place during the study.
The clinical trial protocol is the central document in the study. It must be written in a way that protects the health and welfare of the patients, provide information on why the trial is being conducted, and describe the inclusion and exclusion criteria for recruiting patients. The level of detail included in the trial protocol goes right down to what temperature the investigational medicinal product (IMP) must be stored.
During feasibility, the study team meets with medical doctors who may or may not become involved in the actual trial. Known as Key Opinion Leaders (KOLs), these doctors provide valuable information about the trial. They offer feedback on the existing protocol and propose changes. Information is gathered as to what resources are necessary at each study center to be able to conduct the trial effectively. A seemingly endless series of iterations of protocol revisions and further feasibility is conducted to arrive at the final trial protocol.
Before any drug may be dispensed to the first patient, the protocol must be approved by the Competent Authority of each country that is participating in the study. In the United States, this is the Food and Drug Administration (FDA). The protocol must also be approved by an ethics committee, whose primary role is to safeguard the rights, dignity and well-being of the patients, and also by an institutional review board for each hospital or other institution where patients will be seen.
The ethics committees are particularly interested in the consent form that must be signed before each patient undergoes any procedures and its accompanying patient information sheet (PIS). The PIS must carefully explain each procedure and any anticipated side effects. Each and every risks that are outlined in a separate document for the participating physicians, called the Investigator's Brochure, must be included in the PIS.
Clinical trial management is a lengthy, complicated process. This is necessary to keep bad drugs out of the marketplace and to protect the safety, dignity and well-being of the subjects. It is also necessary to make sure the research answers the right questions.
About the Author:
You can visit the website www.discoveryclinicalresources.com/ for more helpful information about The Clinical Trial Management Life Cycle
0 comments:
Post a Comment